Investors focused on the Medical space have likely heard of Illumina (ILMN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Illumina is a member of our Medical group, which includes 845 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ILMN is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ILMN's full-year earnings has moved 5.24% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ILMN has moved about 56.84% on a year-to-date basis. In comparison, Medical companies have returned an average of 5.39%. This shows that Illumina is outperforming its peers so far this year.
Looking more specifically, ILMN belongs to the Medical - Biomedical and Genetics industry, a group that includes 341 individual stocks and currently sits at #92 in the Zacks Industry Rank. On average, stocks in this group have lost 10.85% this year, meaning that ILMN is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on ILMN as it attempts to continue its solid performance.